XOMA Corp (NASDAQ:XOMA) insider Value Fund L. P. Biotechnology acquired 9,800 shares of the company’s stock in a transaction on Tuesday, December 4th. The stock was bought at an average price of $14.91 per share, for a total transaction of $146,118.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of XOMA opened at $14.98 on Thursday. The company has a current ratio of 5.38, a quick ratio of 5.38 and a debt-to-equity ratio of 19.16. The firm has a market cap of $125.65 million, a PE ratio of 15.29 and a beta of 2.80. XOMA Corp has a 12 month low of $11.88 and a 12 month high of $37.25.
XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.40). The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.83 million. XOMA had a negative return on equity of 267.64% and a negative net margin of 129.85%. Equities research analysts forecast that XOMA Corp will post -1.63 earnings per share for the current fiscal year.
Several research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of XOMA in a research note on Friday, September 21st. ValuEngine lowered shares of XOMA from a “hold” rating to a “sell” rating in a research note on Friday, September 7th. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of XOMA in a research note on Wednesday, August 8th. Zacks Investment Research lowered shares of XOMA from a “hold” rating to a “sell” rating in a research note on Saturday, August 11th. Finally, TheStreet lowered shares of XOMA from a “c-” rating to a “d-” rating in a research note on Monday, November 26th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. XOMA currently has a consensus rating of “Hold” and a consensus price target of $28.07.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd boosted its holdings in shares of XOMA by 57.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock worth $420,000 after buying an additional 7,349 shares during the period. Schwab Charles Investment Management Inc. bought a new stake in shares of XOMA during the 2nd quarter worth $631,000. Dimensional Fund Advisors LP bought a new stake in shares of XOMA during the 2nd quarter worth $568,000. GSA Capital Partners LLP boosted its holdings in shares of XOMA by 135.7% during the 2nd quarter. GSA Capital Partners LLP now owns 28,315 shares of the biotechnology company’s stock worth $591,000 after buying an additional 16,300 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of XOMA by 151.6% during the 2nd quarter. BlackRock Inc. now owns 448,856 shares of the biotechnology company’s stock worth $9,373,000 after buying an additional 270,437 shares during the period. 42.86% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Insider Buying: XOMA Corp (XOMA) Insider Buys 9,800 Shares of Stock” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/12/06/insider-buying-xoma-corp-xoma-insider-buys-9800-shares-of-stock.html.
XOMA Company Profile
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Further Reading: Stop Order
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.